Kurs
+2,20%
Kurs
+2,20%
Open
14,96
High
15,10
Low
14,13
Close
14,67
Kursutveckling under dagen för detta pressmeddelande
(DKK).
Likviditet
0,37 MDKK
Likviditet
0,37 MDKK
Rel. mcap
0,83%
Antal aktier
25 462
Likviditet under dagen för detta pressmeddelande
Kalender
| Est. tid* | ||
| 2025-11-27 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-28 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | N/A | Årsstämma |
| 2025-04-25 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-23 | - | Extra Bolagsstämma 2025 |
| 2025-04-11 | - | X-dag ordinarie utdelning CURAS 0.00 DKK |
| 2025-02-27 | - | Bokslutskommuniké 2024 |
| 2024-11-21 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-07-02 | - | Extra Bolagsstämma 2024 |
| 2024-05-23 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-22 | - | X-dag ordinarie utdelning CURAS 0.00 DKK |
| 2024-03-21 | - | Årsstämma |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-23 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-31 | - | X-dag ordinarie utdelning CURAS 0.00 DKK |
| 2023-03-30 | - | Årsstämma |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-24 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-27 | - | Årsstämma |
| 2022-03-25 | - | X-dag ordinarie utdelning CURAS 0.00 DKK |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-25 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-24 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-01 | - | Extra Bolagsstämma 2021 |
| 2021-05-20 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-26 | - | X-dag ordinarie utdelning CURAS 0.00 DKK |
| 2021-03-25 | - | Årsstämma |
| 2021-02-24 | - | Bokslutskommuniké 2020 |
| 2020-11-30 | - | Kvartalsrapport 2020-Q3 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Spotlight DK |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2022-02-01 08:41:51
Danish Curasight develops its drug candidates uTRACE and uTREAT for diagnosis and treatment of several cancer indications. BioStock recently took a closer look at the potential seen in prostate cancer, and in this article we will dive deeper into the company's ambitions within glioblastoma. With phase IIb results pending, preparations for phase III with uTRACE are being made, all while advancing the preclinical uTREAT project.
Read the full article at biostock.se:
https://www.biostock.se/en/2022/02/biostock-takes-a-closer-look-at-curasights-potential-in-brain-cancer/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se